Apert syndrome is a
genetic disorder characterised by
craniosynostosis and structural discrepancy of the craniofacial region as well as the hands and feet. This condition is closely linked with
fibroblast growth factor receptor-2 (FGFR2) gene mutations. Gene
therapies are progressively being tested in advanced clinical trials, leading to a rise of its potential clinical indications. In recent years, research has made great progress in the gene therapy of
craniosynostosis syndromes and several studies have investigated its influences in preventing/diminishing the complications of
Apert syndrome. This article reviewed and exhibited different techniques of gene therapy and their influences in
Apert syndrome progression. A systematic search was executed using electronic bibliographic databases including PubMed, EMBASE, ScienceDirect, SciFinder and Web of Science for all studies of gene therapy for
Apert syndrome. The primary outcomes measurements vary from
protein to gene expressions. According to the findings of included studies, we conclude that the gene therapy using FGF in
Apert syndrome was critical in the regulation of
suture fusion and patency, occurred via alterations in cellular proliferation. The superior outcome could be brought by
biological therapies targeting the FGF/FGFR signalling. More studies in molecular genetics in
Apert syndrome are recommended. This study reviews the current literature and provides insights to future possibilities of genetic therapy as intervention in
Apert syndrome.